Special Issue

Carbon-Based Nanomaterials as Multifunctional Nanoplatforms for Cancer Diagnosis and Treatment

Message from the Guest Editors

Despite the outstanding advances in cancer diagnosis and therapy, it still remains a leading cause of death worldwide. Current research in nano-oncology is focused on developing cancer-targeted nanoparticles with the ability to overcome drug resistance mechanisms and achieve a more efficient cancer drug delivery with minimal damage to healthy tissues. The optical properties of engineered small graphene fragments have also shown the potential to revolutionize cancer therapy by developing new theranostic nanoparticles for simultaneous imaging and therapy, thus translating the nanoscale science to benefit patients.

The Special Issue aims at collecting full papers, communications, and reviews that clearly demonstrate the ongoing efforts in developing carbon-based materials as nanoplatforms for cancer diagnosis and treatment. This Special Issue aims to cover a broad range of topics, from carbon nanomaterials synthesis to the design and development of nanopharmaceutics to be used as drug delivery systems, imaging agents, and nanotheranostic tools for cancer therapy.

Guest Editors

Dr. Consuelo Celesti

Department of Engineering, University of Messina, Contrada Di Dio, I-98166 Messina, Italy

Prof. Dr. Daniela Iannazzo

Department of Engineering, University of Messina, Contrada Di Dio, I-98166 Messina, Italy

Deadline for manuscript submissions

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/si/127813

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/journal/pharmaceutics

MDPI

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).